Search Results | Blood | American Society of Hematology

1-20 of 128

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Blood (2021) 138 (Supplement 1): 91.

DOI: https://doi.org/10.1182/blood-2021-147913

Published: 2021

Journal Articles

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse

Melhem Solh, Asad Bashey, Scott R. Solomon, Lawrence E Morris, Xu Zhang, H. Kent Holland

Blood (2021) 138 (Supplement 1): 3928.

DOI: https://doi.org/10.1182/blood-2021-151331

Published: 2021

Journal Articles

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi

Blood (2021) 138 (Supplement 1): 2840.

DOI: https://doi.org/10.1182/blood-2021-148948

Published: 2021

Journal Articles

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin Jain, Hagop Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark C. Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal D. Shah

Blood (2021) 138 (Supplement 1): 650.

DOI: https://doi.org/10.1182/blood-2021-153166

Published: 2021

Journal Articles

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Bijal D. Shah, Caron Jacobson, Scott R. Solomon, Nitin Jain, Mark C. Johnson, Monika Vainorius, Lou Yu, Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien

Blood (2021) 138 (Supplement 1): 302.

DOI: https://doi.org/10.1182/blood-2021-150609

Published: 2021

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

DOI: https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Blood (2021) 138 (Supplement 1): 2371.

DOI: https://doi.org/10.1182/blood-2021-152273

Published: 2021

Journal Articles

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Camille Abboud, Sr., Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Sr., Terrence Bradley, JAN Maciej Zaucha, Sr., Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto

Blood (2021) 138 (Supplement 1): 3418.

DOI: https://doi.org/10.1182/blood-2021-151030

Published: 2021

Journal Articles

Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia

Kelli McCrum, Justin LaPorte, Asad Bashey, Scott R. Solomon, Lawrence E Morris, H. Kent Holland, Melhem Solh

Blood (2021) 138 (Supplement 1): 2329.

DOI: https://doi.org/10.1182/blood-2021-151422

Published: 2021

Journal Articles

The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma

Melhem Solh, Asad Bashey, Lawrence E Morris, H. Kent Holland, Xu Zhang, Scott R. Solomon

Blood (2021) 138 (Supplement 1): 2915.

DOI: https://doi.org/10.1182/blood-2021-151056

Published: 2021

Journal Articles

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Katelin C Jackson, Christina L Roark, Brian M Freed, Lawrence E Morris, H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2021) 138 (Supplement 1): 418.

DOI: https://doi.org/10.1182/blood-2021-151496

Published: 2021

Journal Articles

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Melhem Solh, Lawrence E Morris, H. Kent Holland, Katelin C Jackson, Brian M Freed, Christina L Roark, Asad Bashey

Blood (2021) 138 (Supplement 1): 420.

DOI: https://doi.org/10.1182/blood-2021-149289

Published: 2021

Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar

Blood (2021) 138 (Supplement 1): 3845.

DOI: https://doi.org/10.1182/blood-2021-151611

Published: 2021

Journal Articles

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial

Scott R. Solomon, Melhem Solh, Stacey Brown, Nancy Shegda, Katelin C Jackson, Xu Zhang, Lawrence E Morris, Asad Bashey, H. Kent Holland

Blood (2021) 138 (Supplement 1): 1831.

DOI: https://doi.org/10.1182/blood-2021-146091

Published: 2021

Journal Articles

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use

Asad Bashey, Xu Zhang, H. Kent Holland, Lawrence E Morris, Jr., Scott R. Solomon, Melhem Solh

Blood (2021) 138 (Supplement 1): 1780.

DOI: https://doi.org/10.1182/blood-2021-151747

Published: 2021

Journal Articles

HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide

Blood blood.2021013443.

DOI: https://doi.org/10.1182/blood.2021013443

Published: 2021

Includes: Supplemental data

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

DOI: https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Andrea Massimiliano Tomirotti, PhD, Daniela Bellarosa, Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A Strickland, MD MSCI, Roland P Walter, MDPhD, Farhad Ravandi, MBBS, Krzysztof Brzózka, PhD, Milena Mazan, PhD, Simone Baldini, MD, Massimiliano Salerno, Monica Binaschi, PhD, Dirk Laurent, MD, Andrea Pellacani, PhD MD

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-136936

Published: 2020

Journal Articles

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Ephraim J. Fuchs, MD MBA, Shannon R McCurdy, MD, Scott R. Solomon, MD, Tao Wang, PhD, Michelle Kuxhausen, MS, Yvette L Kasamon, MD, MHD Monzr Al Malki, MD, Shahinaz Gadalla, MD PhD, Sophie Paczesny, MDPhD, Steven GE Marsh, BSc, PhD ARCS, Bronwen E. Shaw, PhD MRCP, FRCPath, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Effie Petersdorf, MD

Blood (2020) 136 (Supplement 1): 24–26.

DOI: https://doi.org/10.1182/blood-2020-140433

Published: 2020

Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-136158

Published: 2020

2 3 4 5

NARROW

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia

The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use

HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only